SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon targeting $1 billion revenue by FY19

11 Sep 2017 Evaluate

Biocon is targeting $1 billion revenue by the next fiscal and is betting big on small molecules and generic formulations, biosimilars, branded formulations and research services. The Bengaluru-based firm, which has been chasing the target since 2011, has identified these verticals as its key focus areas. The company had posted a revenue of Rs 4,078.7 crore in 2016-17.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.



Biocon Share Price

418.20 -0.20 (-0.05%)
01-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1865.95
Dr. Reddys Labs. 1339.35
Cipla 1456.95
Zydus Lifesciences 1108.85
Lupin 2396.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: